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An unusual hotspot in a young woman with Hodgkin’s
lymphoma
A young woman has started cancer treatment
because of a Hodgkin’s lymphoma. After four
months of chemotherapy, a PET scan showed an
unexplained hotspot in the right lower abdomen.
This was later explained by an unsuspected preg-
nancy. Our case emphasizes the importance of a
pregnancy test in all women in the reproductive
age before starting cancer treatment.
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Introduction
Malignancy during pregnancy is thought to be extreme-
ly rare. However, in the USA, 1 of any 1000 pregnancies
is accompanied by a malignancy.1 Similar to the incidence
of malignancies of women in the reproductive age, the
most common malignancies are of the cervix, breast and
skin, and hematological malignancies e.g. leukemia and
malignant lymphoma.2
The combination of malignancy and pregnancy is a
major challenge for both the patient and the doctor. The
choice of immediate treatment of the malignancy is often
favorable for the pregnant woman but may be harmful for
the fetus. Different treatment options are possible after
diagnosing a malignancy during pregnancy, such as a ther-
apeutic abortion, starting chemotherapy and/or radiother-
apy while still carrying the fetus or postponing treatment
until the baby is born. Few studies exist with conclusive
outcomes about the risk for the (unborn) child of different
treatment regimens for a malignancy in pregnant women.
In general however, chemotherapy is contraindicated in
the first trimester of pregnancy.1,3
We describe a young woman with an unusual hotspot
on PET scan during treatment for a Hodgkin’s lymphoma.
The hotspot was later explained by an unsuspected preg-
nancy illustrating the importance of performing a preg-
nancy test in all women in the reproductive age before
treatment of malignancies. 
Case report
An 18-year-old woman was referred to our hospital
after being diagnosed with nodular sclerosing Hodgkin’s
lymphoma stage IIA, localized in the mediastinum and
neck. The planned therapy was four courses of ABVD
chemotherapy followed by 30 Gray involved field radio-
therapy. Four months after the start of ABVD-chemother-
apy, an 18F-deoxy-D-glucose (FDG) Positron Emission
Tomography (PET) scan was made for re-evaluation. The
PET scan showed no abnormal uptake at the originally
involved sites, however an unexplained focal accumula-
tion (hotspot) was found in the right lower abdomen
(arrow). Six weeks later, the woman complained of
abdominal distension. An ultrasound showed an unsus-
pected pregnancy with an estimated gestational age of 30
weeks. In retrospect, the hotspot reflected FDG accumu-
lation in the fetal myocardium. The chemotherapy was
given between the 8th and 26th week of gestational age.
The PET scan was made in the 24th week of gestational
age. After 31 weeks of gestation, the patient developed a
HELLP syndrome. A girl was born by caesarian section
without congenital abnormalities. At 6 years of age, she
apparently has a normal development. 
Discussion
Our case shows a very unusual clinical picture of a PET
scan with a very intriguing outcome.
FDG uptake in fetal myocardium reflects the high
myocardial metabolic rate. In fetal myocardium, beta-oxi-
dation of free fatty acids is not possible and therefore oxi-
dation of glucose is the main source of ATP-generation in
fetal myocardium. 
It emphasizes the importance of a pregnancy test in all
women in the reproductive age before starting cancer
treatment. Beside this, it shows the need of an inquiry for
possible pregnancy before administering radio-pharma-
ceuticals to premenopausal woman. In case of doubt a
pregnancy test should be performed. Despite the
chemotherapeutics and the radio-pharmaceuticals admin-
istered during the first and second trimester of the preg-
nancy, the child is developing very well. There does not
exist much evidence about the influence on the fetus of
chemotherapy or the administration of radio-pharmaceu-
ticals for diagnostic purposes during pregnancy. Different
than most other case reports,1,3,4 we show a favorable out-
come for the child after ABVD regimens given during the
first trimester of pregnancy. With respect to the radiation
burdon of a FDG study for the fetus, the radiation dose to
the fetus is considered too low to justify a routine preg-
nancy test in all premenopausal women according to
Dutch nuclear medicine guidelines.5 FDG has been found
to cross the placenta and to accumulate in fetal brain,
heart, and bladder in a monkey study.6 Healthy monkeys
were born but the clinical significance remains uncertain.  
If the pregnancy had been known before starting the
chemotherapy, a difficult decision had to be made. Was
there enough time to delay treatment till after birth, even
if pregnancy was terminated early by caesarian section?
Figure 1. PET scan shows an unex-
plained focal accumulation found in
the right lower abdomen (arrow).
Or would the decision be the same taking into considera-
tion the risks for the fetus? 
As little evidence exists on this subject,4,7 we would like
to emphasize the importance of more research on this
subject and a better registration of concurrent pregnancy
and malignancy.
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